Back to top
more

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)

(Delayed Data from NSDQ)

$7.13 USD

7.13
23,705

+0.33 (4.85%)

Updated Aug 8, 2025 03:59 PM ET

After-Market: $7.13 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock

by Zacks Equity Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Argenx (ARGX) This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.

Zacks Equity Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).